The introduction of the «second wheel» rule in government procurement became a subject of discussion among industry experts at the traditional industry conference «FV» from the «PROektsii Buduschego» series in Sochi on February 15. Opinions were divided: some see it as a measure of support for domestic pharma, while others see it as a project from which Russian patients will lose, reports the correspondent of «FV».
The Association of Russian Pharmaceutical Manufacturers has a very cautious attitude towards the «second wheel», admitted its head Victor Dmitriev. According to him, if the product is competitive, then the «second wheel» is not needed.
According to Dmitriev, domestic manufacturers should be supported, but in other forms: through subsidies, through tax cuts, etc., and the «second wheel» carries many risks and will inevitably «hook» patients.